Trial reportThe Korean journal of internal medicine2017
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study.
Trial report in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- In vitro and in silico studies and a systematic literature review of antiglycation properties of amlodipine.Scientific reports · 2025Pooled it
- Amlodipine: Can act as an antioxidant in patients with transfusion-dependent β-thalassemia? A double-blind, controlled, crossover trial.Journal of clinical laboratory analysis · 2022Trial
- Nanoparticle-based approaches for vascular inflammation in managing hypertension: advancing molecular mechanisms and treatment strategies.Drug delivery and translational research · 2026Review
- A Narrative Review on Nitrate-Rich Diets as Adjuncts to Antihypertensive Therapy: Enhancing Treatment Efficacy via Oxidative Stress Modulation.Biomedicines · 2025Review
- A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension.Frontiers in endocrinology · 2025Observational
- Novel Insights into Amlodipine-Induced Gingival Enlargement: A Clinical and Molecular Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Volume markers in left ventricular diastolic dysfunction and adverse outcomes in peritoneal dialysis patients: a prospective cohort study.Scientific reports · 2023Article
- mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia.International journal of molecular sciences · 2023Review
- The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes.International journal of molecular sciences · 2022Review
- Arterial Hypertension-Oxidative Stress and Inflammation.Antioxidants (Basel, Switzerland) · 2022Review
- Comparison of the Ameliorating Effects of Valsartan and Amlodipine on Vascular Endothelial Dysfunction and Oxidative Stress in Elderly Patients with Type H Hypertension.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress.Frontiers in cardiovascular medicine · 2022Review
- Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.Molecules (Basel, Switzerland) · 2021Article
- Conflicts over calcium and the treatment of COVID-19.Evolution, medicine, and public health · 2021Review
- Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review andOxidative medicine and cellular longevity · 2021Review
- Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.Cell discovery · 2020Article
- Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature.Advances in therapy · 2020Review
- The Role of Oxidative Stress in Physiopathology and Pharmacological Treatment with Pro- and Antioxidant Properties in Chronic Diseases.Oxidative medicine and cellular longevity · 2020Review
- Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.International journal of molecular sciences · 2019Review
- In vivo Assessment of Combined Effects of Glibenclamide and Losartan in Diabetic Rats.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsOxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters.
methodsType 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured.
resultsAfter 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group.
conclusionsValsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.